Lifecore Biomedical (LFCR) Q1 2025 earnings summary

Executive summary

• Streamlined operations, added new leadership, signed four new customers including Lindy Biosciences, and regained NASDAQ compliance in the first 100 days of new CEO tenure.

• Successfully raised $24.3 million through a PIPE/private placement, issuing 5.9 million shares at $4.10 per share, strengthening near-term liquidity.

• Installed and qualified a high-speed multipurpose 5-head isolator filler, more than doubling prior capacity and increasing maximum revenue potential to $300 million annually.

• Lifecore Biomedical operates as a fully integrated CDMO, specializing in sterile injectable pharmaceuticals and premium sodium hyaluronate (HA) production, serving global biopharma and biotech clients.

• Completed the sale of all Curation Foods subsidiaries, with discontinued operations income recognized in the prior year.

Financial highlights

• Q1 2025 revenue was $24.7 million, up $0.2 million or 1% year-over-year, driven by increased HA manufacturing revenues, partially offset by lower CDMO revenues.

• Gross profit rose to $5.4 million from $2.7 million year-over-year, with gross margin improving to 21.8% from 11.1%, due to favorable sales mix and price increases.

• SG&A expenses increased to $14.8 million from $9.2 million, mainly due to higher professional, legal fees, and stock-based compensation.

• Interest expense rose to $5.4 million from $3.9 million, primarily due to debt discount amortization and reduced capitalized interest.

• Net loss widened to $16.2 million ($0.53/share) from $10.8 million ($0.35/share) year-over-year.

• Adjusted EBITDA was ($1.8 million), nearly flat year-over-year.

• Cash balance at quarter-end was $5.5 million, down from $8.5 million at the prior fiscal year-end.

Outlook and guidance

• Fiscal 2025 revenue guidance reaffirmed at $120.5–$130 million, with low 40% of revenue expected in H1 and mid-50% in H2.

• Adjusted EBITDA guidance for FY2025 set at $19–$21 million, with medium-term targets for double-digit revenue growth and improved margins.

• Gross margins expected to remain in the low 30% range, with 30% of gross profit in H1 and 70% in H2.

• SG&A expenses anticipated to be higher in H1 due to non-recurring professional fees, with cost savings expected in H2.

• No plans to raise additional capital in the near term; company expects to be cash neutral in H2 including CapEx.

• Management believes current cash, operational cash flow, available credit, and recent equity offering will support operational and capital needs for at least the next twelve months.